Analysts Offer Predictions for Genmab A/S FY2026 Earnings

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Research analysts at HC Wainwright decreased their FY2026 earnings estimates for Genmab A/S in a research report issued on Friday, November 6th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $1.46 per share for the year, down from their prior forecast of $1.51. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.22 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2026 earnings at $0.34 EPS, Q1 2027 earnings at $0.22 EPS, Q3 2027 earnings at $0.47 EPS, Q4 2027 earnings at $0.47 EPS and FY2027 earnings at $1.60 EPS.

A number of other research analysts also recently issued reports on the stock. Truist Financial restated a “buy” rating and set a $67.00 target price (up from $45.00) on shares of Genmab A/S in a research report on Thursday, October 29th. Guggenheim increased their price target on Genmab A/S from $58.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. New Street Research set a $43.00 price objective on Genmab A/S in a research note on Wednesday, July 22nd. Weiss Ratings raised shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. Finally, TD Cowen lifted their target price on shares of Genmab A/S from $43.00 to $52.00 and gave the company a “buy” rating in a report on Monday, October 26th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Genmab A/S presently has a consensus rating of “Moderate Buy” and an average target price of $53.61.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB opened at $55.80 on Tuesday. The company has a 50 day simple moving average of $39.63 and a two-hundred day simple moving average of $31.22. The stock has a market cap of $34.82 billion, a price-to-earnings ratio of 39.65, a PEG ratio of 2.17 and a beta of 0.73. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. Genmab A/S has a 12 month low of $23.62 and a 12 month high of $59.97.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Thursday, November 5th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.20. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.20 billion.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. WINTON GROUP Ltd lifted its stake in Genmab A/S by 158.9% in the 2nd quarter. WINTON GROUP Ltd now owns 40,900 shares of the company’s stock valued at $1,124,000 after buying an additional 25,100 shares in the last quarter. Diversify Wealth Management LLC purchased a new position in Genmab A/S during the first quarter worth approximately $1,216,000. SummitTX Capital L.P. purchased a new position in Genmab A/S during the first quarter worth approximately $2,263,000. Legacy Wealth Asset Management LLC boosted its stake in Genmab A/S by 164.1% during the second quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company’s stock worth $2,806,000 after buying an additional 63,484 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Genmab A/S by 26.4% during the first quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock worth $118,442,000 after buying an additional 921,700 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases.

The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.

Genmab operates internationally, with activities across Europe, North America and Asia.